Equities analysts expect that Aravive Inc (NASDAQ:ARAV) will report ($0.49) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Aravive’s earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.42). Aravive posted earnings of ($1.20) per share during the same quarter last year, which would indicate a positive year over year growth rate of 59.2%. The firm is expected to issue its next earnings report on Thursday, March 5th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Aravive will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.47). For the next year, analysts anticipate that the business will post earnings of ($2.28) per share, with EPS estimates ranging from ($3.29) to ($1.47). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Aravive.
Aravive (NASDAQ:ARAV) last released its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.04).
A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Aravive in a research note on Friday. Zacks Investment Research cut shares of Aravive from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine raised shares of Aravive from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Piper Jaffray Companies set a $15.00 target price on shares of Aravive and gave the company a “buy” rating in a research note on Friday, September 27th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $13.69.
Aravive stock traded up $0.01 on Tuesday, reaching $6.53. 5,300 shares of the stock were exchanged, compared to its average volume of 23,717. The stock has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The firm has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $6.27. Aravive has a twelve month low of $3.07 and a twelve month high of $9.72. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.17.
In other Aravive news, CEO Jay Shepard sold 4,004 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. 39.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Aravive by 4.7% during the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock worth $955,000 after buying an additional 7,200 shares during the last quarter. BlackRock Inc. grew its stake in Aravive by 5.8% during the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock worth $1,044,000 after buying an additional 9,544 shares during the last quarter. Renaissance Technologies LLC grew its stake in Aravive by 13.8% during the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock worth $890,000 after buying an additional 18,017 shares during the last quarter. Finally, Artal Group S.A. grew its stake in Aravive by 20.0% during the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock worth $1,845,000 after buying an additional 51,197 shares during the last quarter. 28.35% of the stock is currently owned by hedge funds and other institutional investors.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Recommended Story: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com